NASDAQ:APMAptorum Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptorum Group Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.14 +0.20 (+6.80 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$3.05Now: $3.14▼$3.2050-Day Range$3.05MA: $3.26▼$3.6352-Week Range$1.66Now: $3.14▼$33.00Volume31,600 shsAverage Volume24,900 shsMarket Capitalization$90.98 millionP/E RatioN/ADividend YieldN/ABeta0.08 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The company also focuses on the development of surgical robotics and medical devices; and operating outpatient clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in Central, Hong Kong.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aptorum Group. Previous Next 2.5 Community Rank Outperform VotesAptorum Group has received 37 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAptorum Group has received 38 “underperform” votes. (Add your “underperform” vote.)Community SentimentAptorum Group has received 50.67% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aptorum Group and other stocks. Vote “Outperform” if you believe APM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAptorum Group does not currently pay a dividend.Dividend GrowthAptorum Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptorum Group insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.13% of the stock of Aptorum Group is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioAptorum Group has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APM Previous Symbol CUSIPN/A CIKN/A Webwww.aptorumgroup.com Phone852-2117-6611Debt Debt-to-Equity Ratio0.43 Current Ratio3.00 Quick Ratio2.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$540,000.00 Price / Sales168.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book6.16Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees39 Outstanding Shares28,974,000Market Cap$90.98 million Next Earnings Date7/29/2020 (Estimated) OptionableNot Optionable NASDAQ:APM Rates by TradingView Receive APM News and Ratings via Email Sign-up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Aptorum Group (NASDAQ:APM) Frequently Asked Questions How has Aptorum Group's stock been impacted by COVID-19 (Coronavirus)? Aptorum Group's stock was trading at $2.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APM shares have increased by 7.2% and is now trading at $3.14. View which stocks have been most impacted by Coronavirus. When is Aptorum Group's next earnings date? Aptorum Group is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Aptorum Group. Has Aptorum Group been receiving favorable news coverage? Media stories about APM stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptorum Group earned a news impact score of 0.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutAptorum Group. Are investors shorting Aptorum Group? Aptorum Group saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 16,600 shares, a decrease of 5.7% from the April 30th total of 17,600 shares. Based on an average daily trading volume, of 32,400 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the company's shares are short sold. View Aptorum Group's Current Options Chain. Who are some of Aptorum Group's key competitors? Some companies that are related to Aptorum Group include Urovant Sciences (UROV), Kamada (KMDA), Spectrum Pharmaceuticals (SPPI), Seres Therapeutics (MCRB), Wave Life Sciences (WVE), Selecta Biosciences (SELB), TherapeuticsMD (TXMD), Osmotica Pharmaceuticals (OSMT), Geron (GERN), Rigel Pharmaceuticals (RIGL), Bicycle Therapeutics (BCYC), Ovid Therapeutics (OVID), Verrica Pharmaceuticals (VRCA), OrganiGram (OGI) and MannKind (MNKD). View all competitors. What other stocks do shareholders of Aptorum Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptorum Group investors own include Gilead Sciences (GILD), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Inovio Pharmaceuticals (INO), Marina Biotech (MRNA), Sanofi (SNY), Clovis Oncology (CLVS), Laboratory Corp. of America (LH), Matinas BioPharma (MTNB) and SCYNEXIS (SCYX). Who are Aptorum Group's key executives? Aptorum Group's management team includes the following people: Mr. Chung Yuen Huen, Founder, CEO & Exec. Director (Age 39)Mr. Darren Lui, Pres, Chief Bus. Officer & Exec. Director (Age 38)Ms. Sabrina Khan, Chief Financial Officer (Age 37)Dr. Siu-yan Ng, Chief Operating Officer (Age 38)Mr. Clark Cheng, Chief Medical Officer & Exec. Director (Age 39) What is Aptorum Group's stock symbol? Aptorum Group trades on the NASDAQ under the ticker symbol "APM." How do I buy shares of Aptorum Group? Shares of APM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aptorum Group's stock price today? One share of APM stock can currently be purchased for approximately $3.14. How big of a company is Aptorum Group? Aptorum Group has a market capitalization of $90.98 million and generates $540,000.00 in revenue each year. Aptorum Group employs 39 workers across the globe. What is Aptorum Group's official website? The official website for Aptorum Group is www.aptorumgroup.com. How can I contact Aptorum Group? Aptorum Group's mailing address is 17/F GUANGDONG INVESTMENT TOWER 148 CONNAUGHT ROAD CENTRAL, HONG KONG K3, 999077. The company can be reached via phone at 852-2117-6611 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
